SCHEMBL29930722

SCHEMBL29930722

C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1Cc1ccc2onc(N3CCC(=O)NC3=O)c2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TBK1 Q9UHD2 1/20 0.43
▸ DDB1 Q16531 6/20 0.37
▸ CRBN Q96SW2 6/20 0.37
▸ SMARCA2 P51531 1/20 0.36
▸ SMARCA4 P51532 1/20 0.36
▸ PBRM1 Q86U86 1/20 0.36
▸ GPR119 Q8TDV5 7/20 0.36
▸ IDO1 P14902 1/20 0.34
▸ TDO2 P48775 1/20 0.34
▸ IDO2 Q6ZQW0 1/20 0.34
▸ CA12 O43570 2/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ CA4 P22748 2/20 0.34
▸ CA5A P35218 2/20 0.34
▸ CA7 P43166 2/20 0.34
▸ CA5B Q9Y2D0 2/20 0.34
▸ USP30 Q70CQ3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27129616 0.89 PARP1 (0.33) TBK1DDB1CRBN
SCHEMBL27031172 0.89 PARP1 (0.33) TBK1DDB1CRBN
SCHEMBL27031260 0.89 PARP1 (0.33) TBK1DDB1CRBN
SCHEMBL27031245 0.88 IDO1 (0.44) TBK1DDB1CRBNGPR119IDO1
SCHEMBL29930574 0.88 IDO1 (0.44) TBK1DDB1CRBNGPR119IDO1
SCHEMBL31680645 0.86 ALDH1A1 (0.34) TBK1DDB1CRBN
SCHEMBL29930846 0.85 PARP1 (0.43) TBK1DDB1CRBNGPR119IDO1
SCHEMBL27031201 0.85 PARP1 (0.43) TBK1DDB1CRBNGPR119IDO1
SCHEMBL29930847 0.85 DDB1 (0.38) DDB1CRBNGPR119USP30
SCHEMBL27031088 0.85 DDB1 (0.38) DDB1CRBNGPR119USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276964-A1 Benzisoxazole Derivatives and Uses thereof NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2025-09-04 — — US disclosed
EP-4308559-A1 BENZISOXAZOLE DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-01-24 — — EP disclosed
WO-2022195355-A1 BENZISOXAZOLE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2022-09-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276964-A1 Benzisoxazole Derivatives and Uses thereof HBZ, ZFX, WIZ TBK1 2696/4885DDB1 1526/4885CRBN 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback